Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 25

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 25
---
)
promulgated thereunder and Rule 506 of Regulation D promulgated under the Securities Act due to the fact the offering of the February
2025 Warrants and the February 2025 Placement Agent Warrants thereunder did not involve a public offering of securities.

The Company paid H.C. Wainwright & Co., LLC,
the placement agent in the February 2025 Offering, a cash transaction fee equal to 7.5% of the aggregate gross cash proceeds in the offering
and a management fee equal to 1.0% of the aggregate gross cash proceeds in the offering. In addition, the Company paid for certain non-accountable
expenses in the amount of $15,000 and a clearing fee in the amount of $10,000. The Company also issued to the placement agent warrants
to purchase up to 22,554 shares of Common Stock (the “February 2025 Placement Agent Warrants”). The February 2025 Placement
Agent Warrants have an exercise price equal to $4.469 per share and are exercisable upon issuance, or February 6, 2025, and expire twenty-four
months from the date of issuance.

The Company received net proceeds of $908,627
from the offering, after deducting estimated offering expenses paid by the Company, including the placement agent fees. The Company has
used and intends to use the net proceeds from the offering for general corporate purposes, including working capital.

January 2025 Offering

On January 28, 2025, we entered into a securities
purchase agreement (the “January 2025 Securities Purchase Agreement”) with certain institutional investors (the “January
2025 Purchasers”) pursuant to which the Company sold, in a registered direct offering an aggregate of 204,312 shares (the “January
2025 Shares”) of common stock at a purchase price of $5.105 per share in a registered direct offering priced at-the-market under
the rules of Nasdaq. The January 2025 Offering closed on January 30, 2025.

<div align='center'>S-14</div>

The January 2025 Shares were offered pursuant
to a “shelf” registration statement on Form S-3 (Registration No. 333-280796), which was declared effective by the SEC on
July 18, 2024 as supplemented by a prospectus supplement dated January 28, 2025, filed with the SEC on January 30, 2025, and accompanying
base